Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
BioPharma Dive2d
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.